Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH

 
• By Joseph Haas

Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.

Employee or Marketing teams are jointly meta Analysis of strengths, weaknesses and product. Including brainstorming to plan for cooperation
Metacrine is changing course to a focus on IBD, rather than NASH

More from Strategy

More from Business